CRISPR gene-editing therapeutics developer
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 55 | New buy | 137,158 | $1,654,125 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | Trimmed -40% | 78,031 | $941,054 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -78% | 116,700 | $1,407,402 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-01-07 | Cohen Fred E | director | 150,000 | $1,402,500 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.